Upsher-Smith announced that the Food and Drug Administration (FDA) has approved its abbreviated new drug application (ANDA) for Memantine HCl Tablets, the generic version of ActavisNamenda.

Namenda is an NMDA (N-methyl-D-aspartate) inhibitor indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. It is presumed to work as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.

RELATED: Exercise Can Treat Signs and Symptoms of Dementia

Memantine HCl Tablets will be available in 5mg and 10mg strengths.

For more information call (888) 650-3789 or visit